The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerRecent advancements of bortezomib in acute lymphocytic leukemia treatmentTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesmTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell deathSilencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemiaPreclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumorsTwo hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Targeting hypoxia in the leukemia microenvironmentMammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaProtein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.mTORC1 and p53: clash of the gods?Targeting autophagy during cancer therapy to improve clinical outcomes.mTOR kinase inhibitors as a treatment strategy in hematological malignancies.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Additive Damage Models for Cellular Pharmacodynamics of Radiation-Chemotherapy Combinations.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.Acute lymphoblastic leukemia: a comprehensive review and 2017 updatemTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerSynergistic effects of TOR and proteasome pathways on the yeast transcriptome and cell growth.mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress.
P2860
Q26766638-7B7095E7-FFBC-4C1B-964D-27B3E106EC18Q26829613-64035358-C3D3-4DBD-AF41-42BBC7FFF77AQ26829652-F2E026A3-7652-41EA-A865-29A2E0665B0FQ28540672-99CF598F-AC32-47BD-91E2-01AE2F26F9AAQ28541221-B8A2163C-E610-424B-A620-28CCDAE74FA0Q33763742-9A9FB680-EA0C-4E19-BB39-031B67867683Q34260622-B06812B6-18F1-417B-B8BE-3CFB7CA5C705Q34401785-DE127B9D-712D-41A5-A3FF-A9531AB13BC9Q34661672-479FDA3A-551F-48E1-BAD6-1C1D0FB9CA55Q34786480-37262FE6-FC35-4E03-AC3F-74B5451B42BFQ34816101-5C5C6F1B-F648-4148-B611-08C1FF068BD3Q35740894-D572A8A6-ABD4-45DF-90C4-5BE484D7FACCQ36604636-EADDCDD0-759A-410D-85A2-FE8727BD0EB1Q37858077-590121D2-1C1B-452D-85A1-C8C7C90C39EAQ37993588-58562F83-FBF2-4166-9F02-D25E9823C649Q38097334-334DE172-BCAD-479F-BB7A-890158B7DE84Q38604372-B352BE28-2B48-4436-8241-4B5BF8446AD4Q38813978-975E20F0-2C9E-43DE-AC73-51C308FD7B40Q38896592-D11AEF1B-1467-4974-BBC4-8FE3A33139C1Q38987856-0A67E0F6-7D1F-4F49-A110-9E29A20F6184Q39119297-FFFB649B-1E31-43DC-BC1E-F22A66C3EE79Q39249148-20413C42-E017-4526-AD82-128FE7231F1AQ39318989-BB6FBB00-C407-461F-99E0-26627F517336Q39406969-5C63128C-13D1-4DC1-9ABF-C67E8BB66964Q39476954-CAF17710-5424-4C23-986E-9819035D6501Q42600417-0B9245C5-DE85-44B5-8CAC-5587266F9222Q44274584-B8EB1E58-C222-4BB8-9000-414E9D4ABFA8Q47706956-550BABCE-114D-4313-888D-3EC09FE450CBQ53814000-E73F1607-7932-4623-BE84-61AAE454570A
P2860
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@en
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@nl
type
label
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@en
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@nl
prefLabel
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@en
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@nl
P2093
P2860
P1433
P1476
The mammalian target of rapamy ...... -B acute lymphocytic leukemia.
@en
P2093
Adam Cisterne
Jocelyn Weiss
Kenneth F Bradstock
Linda J Bendall
Philip Saunders
P2860
P356
10.3324/HAEMATOL.2010.026997
P577
2010-10-15T00:00:00Z